Support Line: 0800 002 9002
General Enquiries: 01223 870008
  »  Kidney Cancer News  »  CABOSUN trail shines for Cabozantinib

CABOSUN trail shines for Cabozantinib

by | May 4, 2018 | Kidney Cancer News | 0 comments

New CABOSUN Data Show Better PFS With Cabozantinib in mRCC

Read the full article HERE
Updated results from the phase II CABOSUN trial showed cabozantinib significantly prolonged progression-free survival (PFS) per independent review committee compared with sunitinib as first-line therapy for advanced renal cell carcinoma (RCC) of poor or intermediate risk.
Previously available results from CABOSUN showed improved investigator-assessed PFS, with a median PFS of 8.2 months for cabozantinib compared with 5.6 months for sunitinib (P = .012).
“The independent assessment confirms the investigator-assessed results for PFS and supports that cabozantinib is a potential treatment option as initial therapy for patients with advanced RCC of intermediate or poor risk,” Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and colleagues wrote in the European Journal of Cancer.
Clinical TrialsIn the trial, 157 treatment-naive patients with advanced RCC of intermediate or poor risk were randomly assigned to cabozantinib at 60-mg daily or sunitinib at 50-mg daily with 4 weeks on and 2 weeks off. Review by independent committee showed a significant improvement in PFS with cabozantinib. The median PFS was 8.6 months for cabozantinib compared with 5.3 months for sunitinib (hazard ratio [HR], 0.48; 95% CI, 0.31–0.74; P = .0008).
“The observed improvement in PFS with cabozantinib compared with sunitinib may be due, in part, to inhibition of MET and AXL by cabozantinib in addition to VEGF receptors,” the researchers wrote. “Subgroup analyses of PFS based on MET expression level favored cabozantinib over sunitinib (HR < 1) regardless of MET status.”
The overall response rate (ORR) was doubled with cabozantinib compared with sunitinib (20% vs 9%).
Read the full article HERE

<a href="https://www.kcuk.org.uk/author/mp/" target="_self">Malcolm Packer</a>

Malcolm Packer

Malcolm is Chief Executive Officer at Kidney Cancer UK and Kidney Cancer Scotland and has worked with the charity in various capacities for over 15 years.